Skip to main content

. 1990 Dec;53(12):1105. doi: 10.1136/jnnp.53.12.1105

Efficacy of sublingual apomorphine in Parkinson's disease.

F Durif, D Deffond, M Tournilhac

PMCID: PMC488328 PMID: 2292708

1105

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Cotzias G. C., Papavasiliou P. S., Fehling C., Kaufman B., Mena I. Similarities between neurologic effects of L-dipa and of apomorphine. N Engl J Med. 1970 Jan 1;282(1):31–33. doi: 10.1056/NEJM197001012820107. [DOI] [PubMed] [Google Scholar]
Lhermitte F., Agid Y., Signoret J. L. Onset and end-of-dose levodopa-induced dyskinesias. Possible treatment by increasing the daily doses of levodopa. Arch Neurol. 1978 May;35(5):261–263. doi: 10.1001/archneur.1978.00500290007002. [DOI] [PubMed] [Google Scholar]
Poewe W., Kleedorfer B., Gerstenbrand F., Oertel W. Subcutaneous apomorphine in Parkinson's disease. Lancet. 1988 Apr 23;1(8591):943–943. doi: 10.1016/s0140-6736(88)91755-2. [DOI] [PubMed] [Google Scholar]
Pollak P., Champay A. S., Gaio J. M., Hommel M., Benabid A. L., Perret J. Administration sous-cutanée d'apomorphine dans les fluctuations motrices de la maladie de Parkinson. Rev Neurol (Paris) 1990;146(2):116–122. [PubMed] [Google Scholar]
Stibe C. M., Lees A. J., Kempster P. A., Stern G. M. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet. 1988 Feb 20;1(8582):403–406. doi: 10.1016/s0140-6736(88)91193-2. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES